The number of COVID-19 vaccination doses administered per 100 people in South Africa rose to 65 as of Oct 27 2023. This dataset includes a chart with historical data for South Africa Coronavirus Vaccination Rate.

About Dataset: WHO COVID-19 Global Data

This dataset provides comprehensive information on the global COVID-19 pandemic as reported to the World Health Organization (WHO). The dataset is available in comma-separated values (CSV) format and includes the following fields:

Daily cases and deaths by date reported to WHO: WHO-COVID-19-global-data.csv

• Date_reported (Date): The date of reporting to WHO.
• Country_code (String): The ISO Alpha-2 country code.
• Country (String): The name of the country, territory, or area.
• WHO_region (String): The WHO regional office to which the country belongs. WHO Member States are grouped into six WHO regions, including AFRO (Regional Office for Africa), AMRO (Regional Office for the Americas), SEARO (Regional Office for South-East Asia), EURO (Regional Office for Europe), EMRO (Regional Office for the Eastern Mediterranean), and WPRO (Regional Office for the Western Pacific).
• New_cases (Integer): The number of new confirmed cases reported on a given day. This is calculated by subtracting the previous cumulative case count from the current cumulative case count.
• Cumulative_cases (Integer): The total cumulative confirmed cases reported to WHO up to the specified date.
• New_deaths (Integer): The number of new confirmed deaths reported on a given day. Similar to new cases, this is calculated by subtracting the previous cumulative death count from the current cumulative death count.- Cumulative_deaths (Integer): The total cumulative confirmed deaths reported to WHO up to the specified date.

In addition to the COVID-19 case and death data, this dataset also includes valuable information related to COVID-19 vaccinations. The vaccination data consists of the following fields:

Vaccination Data Fields: vaccination-data.csv

• COUNTRY (String): Country, territory, or area.
• ISO3 (String): ISO Alpha-3 country code.
• WHO_REGION (String): The WHO regional office to which the country belongs.
• DATA_SOURCE (String): Indicates the data source, which can be either "REPORTING" (Data reported by Member States or sourced from official reports) or "OWID" (Data sourced from Our World in Data COVID-19 Vaccinations).
• DATE_UPDATED (Date): Date of the last update.
• TOTAL_VACCINATIONS (Integer): Cumulative total vaccine doses administered.
• PERSONS_VACCINATED_1PLUS_DOSE (Decimal): Cumulative number of persons vaccinated with at least one dose.
• TOTAL_VACCINATIONS_PER100 (Integer): Cumulative total vaccine doses administered per 100 population.
• PERSONS_VACCINATED_1PLUS_DOSE_PER100 (Decimal): Cumulative persons vaccinated with at least one dose per 100 population.
• PERSONS_LAST_DOSE (Integer): Cumulative number of persons vaccinated with a complete primary series.
• PERSONS_LAST_DOSE_PER100 (Decimal): Cumulative number of persons vaccinated with a complete primary series per 100 population.
• VACCINES_USED (String): Combined short name of the vaccine in the format "Company - Product name."
• FIRST_VACCINE_DATE (Date): Date of the first vaccinations, equivalent to the start/launch date of the first vaccine administered in a country.
• NUMBER_VACCINES_TYPES_USED (Integer): Number of vaccine types used per country, territory, or area.
• PERSONS_BOOSTER_ADD_DOSE (Integer): Cumulative number of persons vaccinated with at least one booster or additional dose.
• PERSONS_BOOSTER_ADD_DOSE_PER100 (Decimal): Cumulative number of persons vaccinated with at least one booster or additional dose per 100 population.

In addition to the vaccination data, a separate dataset containing vaccination metadata is available, including information about vaccine names, product names, company names, authorization dates, start and end dates of vaccine rollout, and more.

Vaccination metadata Fields: vaccination-metadata.csv

• ISO3 (String): ISO Alpha-3 country code
• VACCINE_NAME (String): Combined short name of vaccine: "Company - Product name" (see below)
• PRODUCT_NAME (String): Name or label of vaccine product, or type of vaccine (if unnamed).
• COMPANY_NAME (String): Marketing authorization holder of vaccine product.
• FIRST_VACCINE_DATE (Date): Date of first vaccinations. Equivalent to start/launch date of the first vaccine administered in a country.
• AUTHORIZATION_DATE (Date): Date vaccine product was authorized for use in the country, territory, area.
• START_DATE (Date): Start/launch date of vaccination with vaccine type (excludes vaccinations during clinical trials).
• END_DATE (Date): End date of vaccine rollout
• COMMENT (String): Comments related to vaccine rollout
• DATA_SOURCE (String): Indicates data source - REPORTING: Data reported by Member States, or sourced from official re...

Morbidity and mortality attributable to COVID-19 is devastating global health systems and economies. Bacillus Calmette Guérin (BCG) vaccination has been in use for many decades to prevent severe forms of tuberculosis in children. Studies have also shown a combination of improved long-term innate or trained immunity (through epigenetic reprogramming of myeloid cells) and adaptive responses after BCG vaccination, which leads to non-specific protective effects in adults. Observational studies have shown that countries with routine BCG vaccination programs have significantly less reported cases and deaths of COVID-19, but such studies are prone to significant bias and need confirmation. To date, in the absence of direct evidence, WHO does not recommend BCG for the prevention of COVID-19. This project aims to investigate in a timely manner whether and why BCG-revaccination can reduce infection rate and/or disease severity in health care workers during the SARS-CoV-2 outbreak in South Africa. These objectives will be achieved with a blinded, randomised controlled trial of BCG revaccination versus placebo in exposed front-line staff in hospitals in Cape Town. Observations will include the rate of infection with COVID-19 as well as the occurrence of mild, moderate or severe ambulatory respiratory tract infections, hospitalisation, need for oxygen, mechanical ventilation or death. HIV-positive individuals will be excluded. Safety of the vaccines will be monitored. A secondary endpoint is the occurrence of latent or active tuberculosis. Initial sample size and follow-up duration is at least 500 workers and 52 weeks. Statistical analysis will be model-based and ongoing in real time with frequent interim analyses and optional increases of both sample size or observation time, based on the unforeseeable trajectory of the South African COVID-19 epidemic, available funds and recommendations of an independent data and safety monitoring board. The study will be supported by a novel 3D lung organoid model of SARS-CoV-2 infection system that can mimic the cascade of immunological events after SARS-CoV-2 infection to determine and analyse the contribution of cellular components to the impact of BCG revaccination in this study. Given the immediate threat of the SARS-CoV-2 epidemic the trial has been designed as a pragmatic study with highly feasible endpoints that can be continuously measured. This allows for the most rapid identification of a beneficial outcome that would lead to immediate dissemination of the results, vaccination of the control group and outreach to the health authorities to consider BCG vaccination for all qualifying health care workers. Methods This dataset was collected in a clinical randomised control trial under the TASK008-BCG CORONA protocol. The trial was conducted in South Africa. This trial was registered with ClinicalTrials.gov, NCT04379336.

This dataset provides values for CORONAVIRUS VACCINATION RATE reported in several countries. The data includes current values, previous releases, historical highs and record lows, release frequency, reported unit and currency.

Abstract

The COVID-19 Vaccine Survey (CVACS) is a South African national panel study of individuals initially unvaccinated against COVID-19. CVACS is implemented by the Southern Africa Labour and Development Research Unit (SALDRU) based at the University of Cape Town. The same respondents are interviewed twice, a few months apart, in 2021 and then 2022, to gather information about their attitudes, beliefs and intentions regarding COVID-19 vaccination. The purpose of CVACS is to collect high quality, timely, and relevant information on facilitators and barriers to COVID-19 vaccine uptake - including vaccine hesitancy and access constraints - to contribute to the development of data-driven campaigns and programmes to increase COVID-19 vaccination uptake in South Africa. In comparison to Survey 1, Survey 2 collected data on unvaccinated and vaccinated respondents. Final data files are: Unvaccinated (as was in S1) Vaccinated (New to S2) derived (As in S1) Link_File (New in S2 - this links the panel)

Geographic coverage

CVACS was not designed to be, and should not be used as a prevalence study. The data cannot be considered to be nationally representative of all unvaccinated individuals in South Africa.

Analysis unit

Households and individuals

Kind of data

Sample survey data [ssd]

Sampling procedure

CVACS Survey 1 was obtained from a stratified sample drawn from the GeoTerraImage (GTI) 2021 sampling frame (https://geoterraimage.com/), using individuals aged eighteen and older. The sample was primarily stratified across the following categories: province, population group, geographic area type (metro, non-metro urban, non-metro rural) and the neighbourhood lifestyle index (NLI), in groups of NLI 1-2, NLI 3-4, and NLI 5-10. Age categories defined according to the COVID-19 vaccination age groups (18-34, 35-49, 50-59, 60+), and gender were used as further explicit stratification variables. A credit bureau database was linked to this database at the enumeration area level, including individuals who had applied for credit, regardless of the outcome, and individuals who have had a credit check.

The CVACS Sample in Survey 2 included individuals from Survey 1 who were re-interviewed, who fell into two categories: vaccinated between Survey 1 and 2, or those remaining unvaccinated. In order to realise an unvaccinated sample of similar size to Survey 1, a top-up sample of unvaccinated individuals was interviewed. These individuals were drawn from the same sampling frame as Survey 1. Younger and female respondents were less likely to be re-interviewed in Survey 2. The full Survey 2 unvaccinated sample is more skewed to the younger age categories, due to higher vaccination rates among the elderly precluding many from inclusion into the study.

Mode of data collection

Computer Assisted Telephone Interview

Research instrument

Data was collected for Survey 2 with two questionnaires, one for vaccinated and one for unvaccinated respondents. CVACS used computer-assisted telephone interviews (CATI). The CVACS questionnaires were translated into all South African languages and interviews were conducted in the preferred language of the respondent. Most of the survey questions collected individual-level data, with some household level data also collected through the individual questionnaire.

Replication Data for: Assessing COVID-19 vaccine hesitancy, barriers, and uptake in Sub-Saharan Africa The collection includes all processed datasets and code to replicate the tables and figures in the paper.

Central African Republic Coronavirus COVID-19 Vaccination Rate - values, historical data, forecasts and news - updated on November of 2025.

Abstract

This dataset is a subset of the wider population-based Covid-19 surveillance run at the Africa Health Research Institute from 2020 onwards. The dataset covers one complete year of data collection, such that all residents had the opportunity to participate. The dataset specifically provides all observations and variables needed to replicate the analyses described in the journal article “COVID-19 vaccine uptake, confidence and hesitancy in rural KwaZulu-Natal, South Africa between April 2021 and April 2022: a continuous cross-sectional surveillance study” published in PLOS Global Public Health in 2023. The dataset includes variable on Covid vaccine uptake and willingness to take a hypothetical vaccine offer on the day of interview, as well as variables measuring four groups of potential predictors of these vaccine outcomes: demographics (age, sex), pre-existing conditions (information sources, government trust, education, urbanicity), contextual factors (impact of Covid on household economics and community wellbeing, Covid-related stigma, household age composition) and cues to action (recent case counts in KwaZulu-Natal, concern about impact if infected with Covid, knowledge of others with past Covid infection, household vaccination status, depression/anxiety) and interview date.

Geographic coverage

AHRI demographic surveillance area, uMkhanyakude district in northern KwaZulu-Natal

Analysis unit

Individual

Universe

All individuals aged 18 and over resident within the areas of the Africa Health Research Institute Population Intervention Programme

Kind of data

Survey data

Sampling procedure

All adult residents in the geographic area were eligible via an individual face-to-face interview. Multiple attempts were made to reach each individual if necessary. The final sample reflects all those who consented to and completed an interview.

Cleaning operations

Pentaho Data Integration was used to extract the datasets. NESSTAR Publisher was used to document the datasets.

IntroductionAlthough the burden of cervical cancer in Africa is highest, HPV vaccination coverage remains alarmingly low in this region. Providers’ knowledge and recommendation are key drivers of HPV vaccination uptake. Yet, evidence about providers’ knowledge and recommendation practices about the HPV vaccine against a backdrop of emerging vaccine hesitancy fueled by the COVID-19 pandemic is lacking in Africa.MethodsA cross-sectional study was conducted in 2021–2022 among healthcare providers involved in cervical cancer prevention activities in Africa. They were invited to report prior training, the availability of the HPV vaccine in their practice, whether they recommended the HPV vaccine, and, if not, the reasons for not recommending it. Their knowledge about the HPV vaccine was assessed through self-reporting (perceived knowledge) and with three pre-tested knowledge questions (measured knowledge).ResultsOf the 153 providers from 23 African countries who responded to the survey (mean age: 38.5 years, SD: 10.1), 75 (54.0%) were female and 97 (63.4%) were based In countries with national HPV immunization programs. Overall, 57 (43.8%) reported having received prior training on HPV vaccine education/counseling, and 40 (37.4%) indicated that the HPV vaccine was available at the facility where they work. Most respondents (109, 83.2%) reported recommending the HPV vaccine in their practice. Vaccine unavailability (57.1%), lack of effective communication tools and informational material (28.6%), and need for adequate training (28.6%) were the most commonly reported reasons for not recommending the HPV vaccine. While 63 providers (52.9%) reported that their knowledge about HPV vaccination was adequate for their practice, only 9.9% responded correctly to the 3 knowledge questions.ConclusionTo increase HPV vaccination coverage and counter misinformation about this vaccine in Africa, adequate training of providers and culturally appropriate educational materials are needed to improve their knowledge of the HPV vaccine and to facilitate effective communication with their patients and the community.

This dataset contains Twitter posts containing daily updates of location-based COVID–19 vaccine-related tweets from January 2021 to August 2021.

With an existing Twitter account, we applied for Developer Access and were granted access to Twitter Academic Researcher API which allows for over 10 million tweets per month. Then, we created an application to generate the API credentials (access tokens) from Twitter. The access token was used in Python (v3.6) script to authenticate and establish a connection to the Twitter database. To get goe-tagged vaccine-related tweets, we used the python script we developed to perform a historical search (archive search) of vaccine-related keywords with place country South Africa (ZA). By goe-tagged tweets, we refer to Twitter posts with a know location. These vaccine-related keywords include but are not limited to the vaccine, anti-vaxxer, vaccination, AstraZeneca, Oxford-AstraZeneca, IChooseVaccination, VaccineToSaveSouthAfrica, JohnsonJohnson, and Pfizer. The keywords were selected from the trending topic during the period of discussion. A complete list of the keywords is shown below:

Oxford-AstraZeneca, AstraZeneca, JohnsonJohnson, Vaccine, BioNTech, anti-vaccine, jab, Vaccination, Covax, Vaccine Rollout, Sputnik, VaccineToSaveSouthAfrica, IChooseVaccination, TeachersVaccine, AstraZeneca vaccine, Pfizer, J & J, Johonson & Johnson, Moderna, VaccinesWork, VacciNation, Vaccine, Steriod, COVIDvaccine, covax, VaccineEquity, VaccineReady, Jab OR PfizerGang, Scamdemic, Plandemic, Scaredemic, COVID-19, coronavirus, SARS-CoV-2, anti-vaxxers, jab, Pfizer, BioNTech, JJ, Vaccine, JohnsonJohnson Vaccine, Vaccine Rollout, J & J, Sputnik, COVAX, CoronaVac

The preferred language of the tweet is English.

Amidst the COVID-19 vaccination, Twitter is one of the most popular platforms for discussions about the COVID-19 vaccination. These types of discussions most times lead to a compromise of public confidence toward the vaccine. The text-based data generated by these discussions are used by researchers to extract topics and perform sentiment analysis at the provincial, country, or continent level without considering the local communities. The aim of this study is to use clustered geo-tagged Twitter posts to inform city-level variations in sentiments toward COVID-19 vaccine-related topics in the three largest South African cities (Cape Town, Durban, and Johannesburg). VADER, an NLP pre-trained model was used to label the Twitter posts according to their sentiments with their associated intensity scores. The outputs were validated using NB (0.68), LR (0.75), SVMs (0.70), DT (0.62), and KNN (0.56) machine learning classification algorithms. The number of new COVID-19 cases significantly positively correlated with the number of Tweets in South Africa (Corr = 0.462, P < 0.001). Out of the 10 topics identified from the tweets using the LDA model, two were about the COVID-19 vaccines: uptake and supply, respectively. The intensity of the sentiment score for the two topics was associated with the total number of vaccines administered in South Africa (P < 0.001). Discussions regarding the two topics showed higher intensity scores for the neutral sentiment class (P = 0.015) than for other sentiment classes. Additionally, the intensity of the discussions on the two topics was associated with the total number of vaccines administered, new cases, deaths, and recoveries across the three cities (P < 0.001). The sentiment score for the most discussed topic, vaccine uptake, differed across the three cities, with (P = 0.003), (P = 0.002), and (P < 0.001) for positive, negative, and neutral sentiments classes, respectively. The outcome of this research showed that clustered geo-tagged Twitter posts can be used to better analyse the dynamics in sentiments toward community–based infectious diseases-related discussions, such as COVID-19, Malaria, or Monkeypox. This can provide additional city-level information to health policy in planning and decision-making regarding vaccine hesitancy for future outbreaks.

Assessing progress in adherence to preventive measure and vaccine hesitancy in communities

The number of COVID-19 vaccination doses administered in South Africa rose to 38813021 as of Oct 27 2023. This dataset includes a chart with historical data for South Africa Coronavirus Vaccination Total.

This study is part of a multi-country research project that utilizes standardized methods to generate cost evidence on the delivery of COVID-19 (C19) vaccines in Vietnam, Bangladesh, and the Philippines in Asia, and Mozambique, Côte d’Ivoire, the Democratic Republic of Congo, and Uganda in Africa. his was a retrospective, bottom-up costing study that estimated the financial and economic costs incurred by Vietnam’s public health system to deliver C19 vaccines in 2021. Costs were estimated for the initial low-volume period from March to June 2021, as well as the high-volume period that started in July 2021 when eligibility for C19 vaccines was expanded to the general population. The study was conducted from the payer perspective, including costs incurred by the health service providers, the NIHE, and development partners, at all levels of the health system. Data was collected retrospectively in April-May 2022 from a purposively selected sample of 26 vaccination sites within six districts and two provinces (Hanoi and Dak Lak), as well as from the regional and national level Institute for Hygiene and Epidemiology and from development partners. The sample included facility-based sites as well as temporary sites. Costs were disaggregated across program activities and resource types to analyze cost drivers. Volume-weighted average unit costs were estimated through vertical aggregation, first obtaining a total delivery cost per dose for each immunization site including costs incurred at all levels, and then estimating the weighted average across sites with the bootstrap method.

Background: Data on COVID-19 suggests that Black Canadians are disproportionately affected by the disease, with higher percentages of cases and severe outcomes than the general population. Aims of the original study: The study aimed to assess the immune responses to COVID-19 vaccines among Black Canadians and to monitor the duration of immunity. They also aimed to identify any differences in the safety and effectiveness of COVID-19 vaccines between Black and non-Black Canadians. Methods: This cohort study recruited Black Canadians and non-Black Canadians across Canada who had received a COVID-19 vaccine. Blood tests were conducted at four time points over the course of 12 months before and after vaccination, to follow up on their immune response to the vaccine. Participants were also surveyed to find out if they experienced any adverse events after vaccination. Summary of the contributed data: the datasets include 1490 participants from Toronto who completed baseline survey between July 2020 and April 2024. 495 participants (33%) continued follow-up surveys, and 1 new participant was recruited during follow-up stage (contributed one or more times of follow-up visit). All participants gave one or more serology samples between July 2021 and April 2024. For London area, the datasets include 102 participants who completed survey, and all participants gave one serology sample between December 2021 and February 2023. Variables include data in the following areas of information: demographics (age, gender, race-ethnicity, occupation), general health (lung disease, heart disease, immunosuppression, height and weight, flu vaccine), longitudinal follow up for COVID infection (test date and result, hospitalization), SARS-CoV-2 vaccination and serology.

this graph was created in OnlinedatasetWorld:

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16731800%2Ffbe07936049278ac75a3fa16b59faa32%2Fscreenshot.png?generation=1719960437279643&alt=media" alt="">

The Google Health COVID-19 Open Data Repository is one of the most comprehensive collections of up-to-date COVID-19-related information. Comprising data from more than 20,000 locations worldwide, it contains a rich variety of data types to help public health professionals, researchers, policymakers and others in understanding and managing the virus.

Dive into the data View the data in multi-layered graphs and charts, or for more technical users, download it into your systems or solutions to investigate specific topics of concern. The datasets provide current information on COVID-19 cases, deaths, vaccination rates, and hospitalizations. Customize your search with queries on weather, geography, and other variables. Using our visualizer, see contextualized results.

In the West Africa Economic Monetary Union (WAEMU) countries, COVID-19 is expected to affect households in many ways. First, governments might reduce social transfers to households due to the decline in revenue arising from the potential COVID-19 economic recession. Second households deriving income from vulnerable sectors such as tourism and related activities will likely face risk of unemployment or loss of income. Third an increase in prices of imported goods can also negatively impact household welfare, as a direct consequence of the increase of these imported items or as indirect increase of prices of local good manufactured using imported inputs. In this context, there is a need to produce high frequency data to help policy makers in monitoring the channels by which the pandemic affects households and assessing its distributional impact. To do so, the sample of the longitudinal survey is a sub-sample of the Enquête Harmonisée sur les Conditions de Vie des Ménages (EHCVM), a harmonized household survey conducted in 2018/19 household survey in the WAEMU countries.

For Burkina Faso, the survey, which is implemented by the Institut National de la Statistique et la Demographie (INSD), is conducted using cell phone numbers of household members collected during the 2018/19 EHCVM survey. The extensive information collected in the EHCVM provides a rich set of background information for the COVID-19 High Frequency Phone Survey of households. This background information can be leveraged to assess the differential impacts of the pandemic in the country. Every month, the sampled households will be asked a set of core questions on the key channels through which individuals and households are expected to be affected by the COVID-19-related restrictions. Employment, access to basic services, non-labor sources of income are channels likely to be impacted. The core questionnaire is complemented by questions on selected topics that rotate each month. This provides data to the government and development partners in near real-time, supporting an evidence-based response to the crisis.

This study is part of a multi-country research project that utilizes standardized methods to generate cost evidence on the delivery of COVID-19 (C19) vaccines in Vietnam, Bangladesh, and the Philippines in Asia, and Mozambique, Côte d’Ivoire, the Democratic Republic of Congo, and Uganda in Africa. This was a bottom-up costing study to estimate the cost of delivering C19 vaccines in Bangladesh through fixed and temporary vaccination sites. Fixed sites included ministry of health (MOH) hospital-based sites, non-MOH government hospitals, and outreach EPI centers, and temporary sites included school-based and mass campaign sites. The study included start up and recurrent costs incurred by the government and partners for all relevant activities. Data covered the full financial and economic cost incurred at fixed sites and the Expanded Program on Immunization (EPI) headquarters from April to June 2022, and specific time periods for temporary sites between November 2021 and November 2022, as well as labor data for fixed sites from February 2021 to June 2022. Data was collected from 38 vaccination sites, EPI headquarters, and from World Health Organization (WHO) and UNICEF, through a partnership between ThinkWell and the Institute of Health Economics (IHE). This study also estimated costs incurred by beneficiaries to receive the C19 vaccine at fixed urban sites, and a qualitative assessment on the funding flows and operational and financial challenges of the C19 vaccination program.

Objective: We examined incidence of SARS-CoV-2 infection, COVID-19 vaccine uptake and factors associated with complete COVID-19 vaccine uptake among persons of migrant origin in Finland.Methods: Data on laboratory-confirmed SARS-CoV-2 infection and COVID-19 vaccine doses between March 2020 and November 2021 were linked to FinMonik register sample (n = 13,223) and MigCOVID (n = 3,668) survey data using unique personal identifier. Logistic regression was the main method of analyses.Results: Among FinMonik sample, complete COVID-19 vaccine uptake was lower among persons of Russia/former Soviet Union, Estonia, and rest of Africa and higher among persons of Southeast Asia, rest of Asia, and the Middle East/North Africa than among persons originating from Europe/North America/Oceania. Male sex, younger age, migration age (<18 years) and shorter length of residence were associated with lower vaccine uptake among FinMonik sample, whereas younger age, being economically inactive, poorer language skills, experiences of discrimination and psychological distress were associated with lower vaccine uptake among MigCOVID sub-sample.Conclusion: Our Findings point to a further need of tailored and targeted communication and community outreach strategies to increase vaccine uptake among persons of migrant origin.

Vaccine hesitancy in the US throughout the pandemic has revealed inconsistent results. This systematic review has compared COVID-19 vaccine uptake across US and investigated predictors of vaccine hesitancy and acceptance across different groups. A search of PUBMED database was conducted till 17th July, 2021. Articles that met the inclusion criteria were screened and 65 studies were selected for a quantitative analysis. The overall vaccine acceptance rate ranged from 12 to 91.4%, the willingness of studies using the 10-point scale ranged from 3.58 to 5.12. Increased unwillingness toward COVID-19 vaccine and Black/African Americans were found to be correlated. Sex, race, age, education level, and income status were identified as determining factors of having a low or high COVID-19 vaccine uptake. A change in vaccine acceptance in the US population was observed in two studies, an increase of 10.8 and 7.4%, respectively, between 2020 and 2021. Our results confirm that hesitancy exists in the US population, highest in Black/African Americans, pregnant or breastfeeding women, and low in the male sex. It is imperative for regulatory bodies to acknowledge these statistics and consequently, exert efforts to mitigate the burden of unvaccinated individuals and revise vaccine delivery plans, according to different vulnerable subgroups, across the country.

To estimate intention to receive newly introduced adult vaccines among community members and healthcare workers (HCWs) in Lusaka, Zambia in the context of previous COVID-19 vaccine uptake and perceived disease threat and, identify trusted sources of vaccine information. We conducted a cross-sectional survey among a random sample of community members and a convenience sample of HCWs from 13 November to 15 December 2023. We evaluated future vaccination intentions by self-reported COVID-19 vaccine uptake, community role, vaccine type (COVID-19 booster, HIV, tuberculosis, malaria, pneumonia, diarrheal disease), and source of information using adjusted, mixed effects Poisson regression and adjusted probability models. We enrolled 395 (79.2 %) community members and 104 (20.8 %) HCWs (N = 499). There was high intention to receive new vaccines among community members (mean score = 83.6 %) andHCWs (mean score = 86.0 %), though intentions varied by vaccine type. Prior COVID-19 vaccine uptake (0,..., Study design We conducted a cross-sectional survey in Lusaka, Zambia, recruiting community members from randomly selected households in four urban communities with relatively low COVID-19 vaccine uptake and healthcare workers (HCWs) at ten healthcare facilities chosen for diversity in size and geographic location. All participants were recruited from November to December 2023, long after the major COVID-19 waves in southern Africa, including the 2021 Omicron wave that was first reported in South Africa and Botswana. Participants and recruitment strategy Adults aged 18 years and above who resided in Lusaka Province and could provide consent were eligible to participate in the study. For HCWs, eligibility was restricted to those providing direct clinical services to patients or community-based health services. We purposively selected 10 healthcare facilities to recruit HCWs and four high-density, low-income areas (compounds) with low COVID-19 vaccination rates to recruit community members..., , # Intention to receive new vaccines post-COVID-19 pandemic among adults and health workers in Lusaka, Zambia

https://doi.org/10.5061/dryad.z08kprrqk

Description of the data and file structure

Files and variables

File: intent_novel_vaccine-06feb2025_share.csv

Description:Â Dataset used in the analyses found in the Vaccine article entitled "Intention to receive new vaccines post-COVID-19 pandemic among adults and health workers in Lusaka, Zambia" (here).

Variables

• gender: birth sex
• age_cat6: categorical age (six categories)
• hcw_alt: community member [0] or healthcare work (HCW) [1]
• marital: marital status
• religion: reported religion
• educ_cat: education categorically
• employ_cat: employment status categorically
• income_qtile: income quartile
• cov_rev: reported receipt of COVID-19 vaccine
• hiv: HIV status
• intent_flu_alt: intention...,